Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.
Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 1–12 of 203 trials
RecruitingCerebral amyloid angiopathy
Application of Digital Twins’ Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project) (opens on ClinicalTrials.gov)
The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary…
- Study
- Interventional (treatment)
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Recruiting in: Italy
NCT06714097Updated 10 November 2026
RecruitingATTR (transthyretin)
Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis (opens on ClinicalTrials.gov)
Introduction: Transthyretin cardiac amyloidosis (ATTR) is an important cause of heart failure. Cardiac planar radionuclide imaging using 99mTc-labeled bone seeking radiopharmaceuticals is used as…
- Study
- Interventional (treatment)
- Sponsor
- University Hospital, Caen
Recruiting in: France
NCT04535349Updated 9 November 2026
RecruitingNot specified
Essen Amyloidosis Registry (opens on ClinicalTrials.gov)
The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis. The registry…
- Study
- Observational (registry, imaging)
- Sponsor
- University Hospital, Essen
Recruiting in: Germany
NCT06887283Updated 6 November 2026
RecruitingAL (light chain)
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis (opens on ClinicalTrials.gov)
This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
Recruiting in: China
NCT07250269Updated 6 November 2026
RecruitingNot specified
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) (opens on ClinicalTrials.gov)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Eli Lilly and Company
Recruiting in: JapanSouth KoreaTaiwanUnited States
NCT07589595Updated 4 November 2026
RecruitingATTR (transthyretin)
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (opens on ClinicalTrials.gov)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Intellia Therapeutics
Recruiting in: ArgentinaAustraliaAustriaBelgium+22
NCT06128629Updated 4 November 2026
RecruitingATTR (transthyretin)
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis (opens on ClinicalTrials.gov)
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named…
- Study
- Observational (registry, imaging)
- Sponsor
- Idoven 1903 S.L.
Recruiting in: FranceGermanySpainUnited Kingdom+1
NCT06978660Updated 4 November 2026
RecruitingAL (light chain)
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis (opens on ClinicalTrials.gov)
A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Polina Stepensky
Recruiting in: Israel
NCT06971380Updated 4 November 2026
RecruitingNot specified
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE) (opens on ClinicalTrials.gov)
Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and…
- Study
- Observational (registry, imaging)
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Recruiting in: Switzerland
NCT04776824Updated 4 November 2026
RecruitingAL (light chain)
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis (opens on ClinicalTrials.gov)
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Janssen Research & Development, LLC
Recruiting in: BelgiumFranceJapanNetherlands+3
NCT05652335Updated 3 November 2026
RecruitingAL (light chain)
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (opens on ClinicalTrials.gov)
The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- GlaxoSmithKline
Recruiting in: AustraliaUnited KingdomUnited States
NCT07224672Updated 3 November 2026
Not yet recruitingATTR (transthyretin)
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry (opens on ClinicalTrials.gov)
The study design is a prospective registry including asymptomatic and symptomatic patients who carry a pathogenic TTR mutation. The study will enroll patients who…
- Study
- Observational (registry, imaging)
- Sponsor
- Virginia Commonwealth University
Recruiting in: United States
NCT05974644Updated 3 November 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 10 November 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.